Diligence memo · auto-generated · as of July 2, 2026
Marizyme Inc
Marizyme Inc looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Marizyme Inc operates in Biotechnology, based in JUPITER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Marizyme Inc has raised $16M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $15M on 2018-09-12.
Most recent recorded round closed around 2023-05-15.
Valuation (modeled)modeled
Provath models Marizyme Inc at approximately $9.1M (range $1.1M–$25M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.20× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 24 months.
Last raise 3.1 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 3.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 64% of Biotechnology peers (4293 compared).
Modeled value ranks above 17% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.